Sleeping in low light can reverse DME changes

Article

Patients sleeping in a low-lit room may find that the changes in diabetic macular oedema (DME) are reversed.

Patients sleeping in a low-lit room may find that the changes in diabetic macular oedema (DME) are reversed, claims a study in Eye.

Dr G.B. Arden et al., School of Community and Health Sciences, City University, London, UK, conducted an investigation on 40 patients with mild non-proliferative diabetic retinopathy (DR) and early, untreated non-sight threatening DME. For six months all patients slept with a mask that illuminated the eyelid of a single closed eye with a 505 nm light.

The exclusion criteria were the presence of any concomitant eye disease and the primary outcome was the change in OCT retinal thickness where oedema was present.

Of the 40 patients observed, 34 completed the investigation. For study and fellow eyes the mean baseline OCT macular cube thickness was equivalent. It was found that the study eyes presented with a greater thickness in the central subfield zone 1 compared to the fellow eyes.

Intraretinal cysts were found in 28 eyes, compared to 9 found in the fellow eyes. Only 19 study eyes presented with cysts at 6 months, whilst 20 fellow eyes had cysts. In study eyes the worst affected ETDRS zone and the central subfield zone 1 experienced a reduction in thickness by 12μm.

In study eyes visual acuity, achromatic contrast sensitivity and microperimetric thresholds improved and in the fellow eyes they deteriorated.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.